Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Avita Therapeutics Inc (ASX: AVH) is a medical technology company that specialises in regenerative medicine. Avita’s leading product, the RECELL System, was developed to address unmet medical needs in burns. The RECELL System is used to prepare ‘spray-on skin cells’ by using a small amount of the patient’s own skin. This is a revolutionary way to treat severe burns and significantly reduces the amount of donor skin required.
RECELL was granted US Food and Drug Administration (FDA) approval in September 2018 for the treatment of acute thermal burns in patients 18 years and older. Since then, Avita has been undertaking studies to assess the use of the RECELL System in other applications. This includes the treatment of pediatric scald injuries, soft tissue reconstruction and vitiligo.
The Avita share price exploded in 2019, going from $0.081 to finish the year a phenomenal 696% higher at $0.645. With this, Avita earned itself a spot in the S&P/ASX 200 Index (ASX: XJO), as well as a place on many investors’ ASX watchlists.
|23 Jul 2021||$5.17||$-0.14||-2.64%||200,749||$5.25||$5.29||$5.16|
|22 Jul 2021||$5.31||$0.07||1.34%||231,142||$5.34||$5.40||$5.31|
|21 Jul 2021||$5.24||$0.16||3.15%||271,748||$5.20||$5.35||$5.20|
|20 Jul 2021||$5.08||$-0.01||-0.20%||145,497||$5.10||$5.15||$5.06|
|19 Jul 2021||$5.09||$0.01||0.20%||115,157||$5.08||$5.10||$5.04|
|16 Jul 2021||$5.08||$0.02||0.40%||205,584||$5.08||$5.14||$5.02|
|15 Jul 2021||$5.06||$-0.17||-3.25%||320,930||$5.19||$5.20||$5.05|
|14 Jul 2021||$5.23||$-0.05||-0.95%||158,441||$5.29||$5.29||$5.18|
|13 Jul 2021||$5.28||$0.06||1.15%||195,477||$5.25||$5.38||$5.25|
|12 Jul 2021||$5.22||$0.02||0.38%||157,959||$5.20||$5.27||$5.18|
|09 Jul 2021||$5.20||$-0.07||-1.33%||180,773||$5.22||$5.22||$5.13|
|08 Jul 2021||$5.27||$-0.13||-2.41%||306,907||$5.39||$5.39||$5.25|
|07 Jul 2021||$5.40||$0.16||3.05%||330,991||$5.32||$5.40||$5.29|
|06 Jul 2021||$5.24||$-0.07||-1.32%||279,461||$5.32||$5.34||$5.24|
|05 Jul 2021||$5.31||$-0.14||-2.57%||255,035||$5.44||$5.44||$5.30|
|02 Jul 2021||$5.45||$0.07||1.30%||518,888||$5.42||$5.52||$5.32|
|01 Jul 2021||$5.38||$0.15||2.87%||737,549||$5.41||$5.64||$5.33|
|30 Jun 2021||$5.23||$-0.11||-2.06%||486,564||$5.38||$5.39||$5.18|
|29 Jun 2021||$5.34||$-0.22||-3.96%||573,859||$5.54||$5.54||$5.26|
|28 Jun 2021||$5.56||$-0.24||-4.14%||435,286||$5.79||$5.79||$5.53|
|25 Jun 2021||$5.80||$0.33||6.03%||999,498||$5.58||$5.89||$5.55|
|04 Jun 2021||Michael Perry||Exercise||4||$21,235,629||
Conversion of securities. 9,501,400 - RSUs, (consolidation
equivalent = 95,014 unquoted RSUs
in Avita US)
As per announcement on 08/06/2021.
|22 Mar 2021||Michael Perry||Transfer||631||$3,500,000||
As advised by the company. Estimated value
Transfer of CDIs to Dr Perry's former wife in accordance with a marital separation agreement.
As per announcement on 29/03/2021.
|15 Sep 2020||Michael Perry||Exercise||6||$51,652,656||
Conversion of securities. 14,252,098 - RSU's
consolidation equivalent = 142,521 unquoted RSUs in Avita US).
|09 Sep 2020||Michael Perry||Exercise||8||$60,000,004||
Conversion of securities. 21,102,583 - RSUs
As per announcement on 14/09/2020.
|Mr Louis (Lou) James Panaccio||Non-Executive ChairmanNon-Executive Director||Jul 2014||
Mr Panaccio is healthcare businessman with experience leading companies from concept to commercialization. Mr Panaccio has more than 30 years of executive leadership experience in healthcare services and life sciences, including more than 20 years of board-level experience. Mr Panaccio is Non-Executive Director of Unison Housing Limited, was Non-Executive Chairman of Genera Biosystems Limited until June 2019.
|Professor Suzanne Crowe||Non-Executive Director||Jan 2016||
Professor Crowe has experience in supporting companies with their medical and scientific strategies. She is a Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne and Adjunct Professor of Medicine and Infectious Diseases at Monash University, Melbourne. Professor Crowe is a is a Director of St Vincents Health Australia. He is Chair of Compensation Committee.
|Mr Jeremy Curnock-Cook||Non-Executive Director||Oct 2012||
Mr Cook is currently the Managing Director of Bioscience Managers Pty Ltd, a formerly a shareholder of the Company, responsible for the BM Asia Pacific Healthcare Fund, and serves as Chairman of International Bioscience Managers Ltd. He is the former head of the life science private equity team at Rothschild Asset Management and was responsible for the launch of the biotechnology fund for the Australian market and the conception and launch of the International Biotechnology Trust. From November 2005, he also serves as a Director for AmpliPhi Biosciences Corporation, Inc. (which merged to Armata Pharmaceuticals, Inc. in May 2019). He also serves as a Director for Sea Dragon Limited. Mr Cook previously served as a Non-Executive Director of Phylogica Limited. He is Member of Compensation Committee.
|Dr Michael S Perry||Chief Executive OfficerExecutive Director||Feb 2013||
Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC. Dr Perry serves as a Director of Arrowhead Pharmaceuticals. He is also a Director at BioScience Managers Pty Ltd.
|Mr Louis Drapeau||Non-Executive Director||Jan 2016||
Mr Drapeau has experience in both the biotech sector and with the financial reporting and other requirements of U.S. public companies. From March 2011 until May 2019, Mr Drapeau served as an Independent Director at AmpliPhi Biosciences Corporation, Inc. Mr. Drapeau has held senior positions with Insite Vision Inc., Nektar Therapeutics and BioMarin Pharmaceutical, Inc., and served as an Audit Partner at Arthur Andersen LLP. Mr. Drapeau was previously an Independent Director at Bio-Rad Laboratories and InterMune, Inc. He is Member of Compensation Committee.
|Ms Jan Stern Reed||Non-Executive Director||Jul 2021||
Ms Reed has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and also has experience in corporate governance, compliance and risk management. Most recently, she was Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacyled, health and wellbeing company. Prior to Walgreens, Ms Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions. Prior to Solo Cup Company, she was Associate General Counsel, Corporate Secretary and Chief Corporate Governance Officer at Baxter International, Inc. Ms Reed currently serves as a board member of Stepan Co. (NYSE:SCL) and AngioDynamics, Inc. (NASDAQ: ANGO).
|Mr James Corbett||Non-Executive Director||Jul 2021||
Mr Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr Corbett has global commercial and operating experience, serving as an expatriate General Manager of Baxter Japan and later as General Manager and President of Scimed Life Systems Inc. and Boston Scientific International respectively. During his career he has served as CEO of 3 publicly listed companies; Microtherapeutics Inc (MTIX), ev3 Inc (evvv), Alphatec Spine (ATEC). Mr Corbett has also led two privately funded companies as CEO; Home Diagnostics Inc. and Vertos Medical. Mr Corbett has capital market and governance experience from both public and private environments.
|Mr Mark Andrew Licciardo||Company Secretary||Mar 2018||
|Erin Liberto||Chief Commercial Officer||
|David McIntyre||Chief Financial Officer||
|Andrew Quick||Chief Technology Officer||
|Mark Andrew Licciardo||Company Secretary||
|Donna Shiroma||General Counsel||
|Cede & Co||40,188,890||37.44%|
|HSBC Custody Nominees (Australia) Limited (I)||7,253,182||6.76%|
|Citicorp Nominees Pty Limited||7,045,639||6.56%|
|J P Morgan Nominees Australia Pty Limited||6,687,839||6.23%|
|National Nominees Limited||5,395,728||5.03%|
|Merrill Lynch (Australia) Nominees Pty Limited||1,816,130||1.69%|
|Mr Michael Perry||1,263,045||1.18%|
|HSBC Custody Nominees (Australia) Limited Gsco Eca||1,252,369||1.17%|
|Cs Fourth Nominees Pty Limited||1,097,835||1.02%|
|HSBC Custody Nominees (Australia) Limited (II)||735,579||0.69%|
|Ateq Investments Pty Ltd||590,000||0.55%|
|BNP Paribas Nominees Pty Ltd||490,104||0.46%|
|BNP Paribas Nominees Pty Ltd (I)||412,302||0.38%|
|Warbont Nominees Pty Ltd||403,116||0.38%|
|Brispot Nominees Pty Ltd||359,195||0.33%|
|Mr Adrian Simun Puljich||271,765||0.25%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd||244,938||0.23%|
|Dibbens Developments Pty Limited||225,000||0.21%|
|Mr Anthony Mark Saia & Mrs Carmen Saia||217,500||0.20%|
|Citicorp Nominees Pty Limited (I)||213,979||0.20%|
Avita Therapeutics shares do not currently include a dividend payment. The company has made no announcements regarding paying a dividend in 2020.
No, Avita Therapeutics does not currently offer a dividend reinvestment plan (DRP).